← Back
Quoin Pharmaceuticals
QNRX · listed on Nasdaq · worth $19.26 million
$4.01
−0.25% on Oct 26
Four insider buys in the last year, $280K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
1.9M shares
40% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought Quoin Pharmaceuticals stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Operating Officer
Denise P. Carter
Bought $100K on Aug 31 — 20,490 shares at $4.88, 54% of what they now own.
First purchase we have on file
Chief Executive Officer
Michael Myers
Bought $100K on Aug 31 — 20,490 shares at $4.88, 54% of what they now own.
First purchase we have on file
Chief Financial Officer
Sally Bridget Lawlor
Bought $50K on Aug 31 — 10,244 shares at $4.88, 96% of what they now own.
First purchase we have on file
Big investors
People and funds that reported owning 5% or more of Quoin Pharmaceuticals, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateIkarian Capital4.4%Oct 7
All reports
Every insider trade and SEC report we hold for Quoin Pharmaceuticals.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Sep 1BoughtSally Bridget LawlorSep 1 · Traded Aug 31 · Chief Financial Officer+96%10,244 @ $4.88$50K
Oct 15, 2025BoughtDennis LangerOct 15, 2025 · Traded Oct 14, 2025 · Director+100%15,152 @ $8.49$128.6K
Analysts, earnings and news
Analysts' price target
$21.40 average
5 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26−$1.90 a share−$0.13
Q1 '26−$1.77 a share+$0.49
Q4 '25−$1.74 a share+$2.28
Q3 '25−$6.70 a share−$4.78